Summit Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
Business Address
601 BRICKELL KEY DRIVE, MIAMI, FL, 33131
Mailing Address
601 BRICKELL KEY DRIVE, MIAMI, FL, 33131
Phone
305-203-2034
Fiscal Year End
1231
EIN
371979717
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 10-K Annual financial report | February 23, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Annual Reports
10-K
February 23, 2026
- Akeso-001, lead drug for NSCLC, successfully completed Phase 3 patient enrollment, with top-line data expected in 2026.
- Strong cash position of $450.1 million, expected to fund operations into late 2027, bolstered by a strategic partnership with PharmaGiant Corp.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.